Navigation Links
PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
Date:3/11/2008

BOSTON, March 11 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL) announced today it will be presenting at the Lehman Brothers 11th Annual Global Healthcare Conference in Miami, Florida. Josef von Rickenbach, Chairman and Chief Executive Officer will be making a formal presentation on PAREXEL at 4:15 p.m. EDT on Wednesday, March 19, 2008.

A live webcast of this presentation will be available through the "Investor Relations Webcasts" section of PAREXEL's web site at http://www.PAREXEL.com and a replay of the presentation will be available until June 19, 2008.

About the Company

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has over 7,050 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.

PAREXEL is a registe
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
2. PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting
3. PAREXEL International Announces 2-For-1 Stock Split
4. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
5. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
6. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
9. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
10. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
11. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
(Date:12/24/2014)... Dec. 23, 2014 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... its majority-owned subsidiary, Shandong Taibang Biological Products Co. ... from the China Food and Drug Administration (the ... As previously disclosed in the Company,s public filings, ...
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Oxford Biomedica,s,second attempt to dismiss Bavarian Nordic,s patent ... denying infringement, Oxford Biomedica,made yet another attempt to dismiss ... still evaluated in clinical trials. The court ruled,against Oxford ... the,substance of the patents. , ...
... 8 Sinovac Biotech Ltd. (Amex: SVA ), ... it will host a conference call on Friday, May 15, ... quarter financial results for the period ended March 31, 2009 ... conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). ...
... (Nasdaq: NVAX) today announced financial results for ... of $8.3 million, or $0.12 per share, for the first quarter ... $0.13 per share, for the first quarter of 2008. The ... of 2009 and ended the quarter with $25.6 million in cash ...
Cached Biology Technology:The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica 2Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results 2Novavax Reports First Quarter 2009 Financial Results 2Novavax Reports First Quarter 2009 Financial Results 3Novavax Reports First Quarter 2009 Financial Results 4Novavax Reports First Quarter 2009 Financial Results 5Novavax Reports First Quarter 2009 Financial Results 6Novavax Reports First Quarter 2009 Financial Results 7Novavax Reports First Quarter 2009 Financial Results 8
(Date:12/10/2014)... -- CIE San Diego has launched an innovative trust ... that enhances care coordination among social service and care ... earned a second $1 million grant from the Alliance ... in community and; will be recognized as a "Live ... 4-6p. CIE San Diego today announced the ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Houston Cullen College of Engineering has won a grant to ... disease safer and more effective. The grant goes to ... the National Science Foundation, it is valued at $330,000 for ... Abosch, an M.D./Ph.D a neurosurgeon with the University of Colorado ...
... more than a decade PETA and its affiliates ... organisations worldwide, providing the European Union (EU) and ... with technical expertise in modern, reliable, non-animal research ... PETA US, PETA UK and their European and ...
... that individuals with the highest metabolic rates within populations ... changes in their environments that could lead them to ... however should be constantly monitoring their opportunities for higher ... shows that variation in metabolic rates between individuals can ...
Cached Biology News:Parkinson's Surgery Research wins NSF Grant 2PETA and its international affiliates launch not-for-profit international science company 2Gathering information about food is not top priority for individuals with high metabolisms 2
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
... monitoring Aldolase tests. 2 levels of ... manufacturing values at 4 ± 2 ... 30-day shelf life once opened ... 1: 3 x 3 ml; Level ...
Human VEGF-D Biotinylated MAb (Clone 78923)...
Mouse Wnt-11 Affinity Purified Polyclonal Ab...
Biology Products: